Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Pharmaceutical firm Roche has scored an exit after US-based vaccine developer Vaxcyte floated on the Nasdaq Global Select Market in a $250m initial public offering. The company priced more than 15.6 million shares at $16.00 each having previously set a range of $14 to $16 for 14 million shares. It floated on Friday and its…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.